Among these, SLC1A5 (also known as ASCT2), SLC7A5 (LAT1) and its heavy chain SLC3A2 (CD98hc), and SLC38A1 (SNAT1) are highly expressed in various cancers and have been implicated in tumor progression, therapeutic resistance and clinical outcome [7, 26–38]. Here, SLC7A5 is linked to neoplasm.